EVE.SW EvoNext Holdings S.A. (SIX) down 7.56% 16 Mar 2026: buy-sell signal

Market closed: EVE.SW stock slid 7.56% to CHF 0.83 on 16 Mar 2026 after opening at CHF 0.93. Trading volume was light at 1,587 shares versus an average of 8,084. The move left the share price below the 50‑day average of CHF 0.86 and well under the 200‑day average of CHF 0.95. Below we break down valuation, technical signals, the Meyka AI grade, and a model forecast to frame risks and short and medium term targets for EvoNext Holdings S.A.

EVE.SW stock price action and session context

EVE.SW stock closed at CHF 0.83, down 7.56% from the previous close of CHF 0.90. The intraday range was CHF 0.82 to CHF 0.93.

Trading was thin with 1,587 shares changing hands, 0.22 relative volume. The stock remains nearer its year low of CHF 0.75 than its year high of CHF 1.45.

EVE.SW stock fundamentals and valuation

EvoNext Holdings S.A. reports EPS -0.12 and a trailing PE of -6.93, reflecting negative earnings. Book value per share is CHF 0.86 and cash per share is CHF 0.87, giving a tangible cushion relative to the market price.

Market capitalization is about CHF 6,000,011.00 and the price to book is 1.04. The current ratio is 8.34, indicating short‑term liquidity but limited revenue scale.

EVE.SW stock technicals and liquidity

Technically the stock shows oversold signals. RSI is 44.74, CCI is -122.30, and ADX is 51.71, which signals a strong trending move. Bollinger bands sit at 0.99/0.91/0.83 (upper/mid/lower).

Average daily volume is 8,084 shares versus today’s 1,587, so liquidity is thin. Support is close to the year low CHF 0.75 and near‑term resistance sits around the 50‑day average CHF 0.86.

Meyka AI rates EVE.SW with a score out of 100 and forecast

Meyka AI rates EVE.SW with a score of 68 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecast alignment, and analyst signals.

Meyka AI’s forecast model projects a 12‑month target of CHF 1.46, a monthly level of CHF 0.81, and a quarterly model at CHF 0.54. Versus the current CHF 0.83, the 12‑month model implies ~76.00% upside. Forecasts are model‑based projections and not guarantees.

Risks, sector context and catalysts for EVE.SW stock

EvoNext trades in the Swiss Healthcare and Biotechnology sector, which has an average PE near 29.52. That sector trades at a premium to EvoNext’s metrics, highlighting relative valuation risk and execution dependence.

Key risks include persistent negative EPS, low revenue scale, and limited analyst coverage. Catalysts would be clearer revenue growth, corporate partnerships, or positive product updates ahead of the earnings date on 2026-08-20.

Trading strategy, short targets and price levels for EVE.SW stock

Near term, traders should watch support at CHF 0.75 and resistance at CHF 0.91 and CHF 0.99 (Bollinger upper). A break below CHF 0.75 would signal further downside pressure.

Longer term, model-based upside to CHF 1.46 assumes recovery in revenues or a re‑rating. A conservative short‑term target based on the quarterly model is CHF 0.54, while the 12‑month target is CHF 1.46.

Final Thoughts

EVE.SW stock closed the Swiss session down 7.56% at CHF 0.83 on 16 Mar 2026. The company shows a liquid cash buffer of CHF 0.87 per share and a book value near CHF 0.86, yet it posts negative earnings of EPS -0.12 and a trailing PE of -6.93. Technicals are oversold and volume is thin, which increases short‑term volatility. Meyka AI rates EVE.SW at 68/100 (Grade B, HOLD) and its model projects a 12‑month target of CHF 1.46, implying roughly 76.00% upside from the current price of CHF 0.83. That projection assumes improved revenue or a corporate catalyst. Investors should weigh the high downside risk from weak earnings and small market cap against the model upside. Meyka AI, the AI‑powered market analysis platform, flags EVE.SW as a speculative holding best suited for risk‑aware investors who can tolerate low liquidity and binary biotech outcomes. Forecasts are model‑based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.